SCHEMBL29566934

SCHEMBL29566934

CCc1c(Oc2cccc(N3CCN(C)CC3)c2F)nc(NS(=O)(=O)c2cnn(C)c2)nc1-c1ccccc1C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 8/20 0.39
▸ HTR1A P08908 7/20 0.39
▸ HTR6 P50406 4/20 0.39
▸ DRD2 P14416 3/20 0.39
▸ HTR2A P28223 3/20 0.34
▸ EGFR P00533 3/20 0.34
▸ BRPF1 P55201 2/20 0.33
▸ BRD9 Q9H8M2 2/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ MAPT P10636 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ TNK2 Q07912 1/20 0.32
▸ APAF1 O14727 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310020 1.00 HTR7 (0.39) HTR7HTR1AHTR6DRD2HTR2A
SCHEMBL24309480 0.92 DRD2 (0.39) HTR7HTR1AHTR6DRD2HTR2A
SCHEMBL29566939 0.90 BRD9 (0.36) HTR7HTR1AHTR6DRD2HTR2A
SCHEMBL24310358 0.90 BRD9 (0.36) HTR7HTR1AHTR6DRD2HTR2A
SCHEMBL24310629 0.88 HTR1A (0.36) HTR7HTR1AHTR6DRD2HTR2A
SCHEMBL29567378 0.88 HTR1A (0.36) HTR7HTR1AHTR6DRD2HTR2A
SCHEMBL24310028 0.85 BRPF1 (0.32) BRPF1BRD9BRD4TNK2
SCHEMBL29567208 0.85 HTR6 (0.41) HTR7HTR1AHTR6DRD2HTR2A
SCHEMBL24309753 0.85 HTR6 (0.41) HTR7HTR1AHTR6DRD2HTR2A
SCHEMBL24310029 0.84 HTR6 (0.35) HTR7HTR1AHTR6DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback